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To be really useful, a vaccine must be highly efficacious, safe,
and must be accepted by and administered to the majority
of the target population. Current prophylactic vaccines against
human papillomavirus (HPV), based on L1 virus-like particles,
have been extensively evaluated for both efficacy against severe
precancerous lesions of the cervix uteri and safety (Schiller et al,
2008). On account of a spectacular 100% efficacy in young women
not infected with the HPV vaccine types (HPV16/18), the vaccines
have been incorporated into national immunisation programmes
in the United States and several European countries (Austria,
France, Germany, Italy, and the United Kingdom) faster than
any vaccine ever before. Immunisation against HPV in
combination with cervical screening has the potential to eradicate
cervical cancer.
Current HPV vaccines were the product of 100 years of
epidemiological data on the association between cervical cancer
and a sexually transmitted agent, and 20 years of firm biological
evidence that a few mucosal HPV types (denominated oncogenic
types) were such agents (IARC, 1995). Although some 20 different
HPV types were known to infect the genital tract (IARC, 1995),
vaccine research had focused since the beginning on two
oncogenic HPV types (HPV16/18). Two non-oncogenic types
(HPV6 and 11) were also intensively studied for the purpose of
preventing genital warts. However, the decision to develop a
vaccine against HPV16 (Koutsky et al, 2002), and subsequently
HPV18, was made based on relatively few studies that were small
in size, and that often tested for very few oncogenic HPV types
other than HPV16/18 (IARC, 1995).
Information from over 30000 invasive cervical cancers from five
continents has now accumulated, and has not only confirmed the
predominance of HPV16 (57%) and HPV18 (16%) in every studied
population, but has also showed the similarity in the relative
importance of other oncogenic types (HPV31, 33, 35, 45, 52, and
58) (Li et al, 2010).
In the present issue of the British Journal of Cancer, Howell-
Jones et al provide information on the prevalence of oncogenic
HPV types across the full spectrum of cervical pathology, from
normal to cancer, in a nationally representative sample of 6234
women in England. The study, one of the largest and most accurate
ever carried out, represents a robust baseline picture against which
changes in HPV prevalence and type distribution following the
introduction of the HPV Vaccination Programme in 2008 in
England can be evaluated (Department of Health, 2010). The
prevalence of HPV16 was low among women without cytological
abnormalities (3%), but it greatly increased in women with cervical
intraepithelial neoplasia grade 3 (CIN3) (57%), squamous cell
carcinoma (66%), and adenocarcinoma (48%) of the cervix.
Infection with HPV18 was rarer than HPV16 in women without
cytological abnormalities (1%), and in those with CIN3 (8%), and
squamous cell carcinoma (13%), but nearly equally frequent (40%)
in women with adenocarcinoma.
Howell-Jones et al also emphasised the difficulties of attributing
a cervical cancer or precancerous lesion to an individual HPV
type in the presence of multiple-type infections. Concurrent
detection of two HPV types or more has become increasingly
frequent in the last 20 years (Li et al, 2010) on account of the
use of more and more sensitive HPV tests (e.g. the Linear Array
typing system (Roche Molecular Systems, Inc., Branchburg, NJ,
USA) used by Howell-Jones et al). Immunisation against HPV16/18
in England has, therefore, the potential to prevent 56–65% of CIN3
and 73–77% of invasive cervical cancer. Finally, cross-protection
against oncogenic types other than HPV16/18 may prevent an
additional 3–4% of invasive cervical cancer.
The multi-site HPV prevalence study by Howell-Jones et al also
highlighted the high frequency of infection with oncogenic HPV
types among women in England. Prevalence was 16% among
all screened women, but rose to 29% among women aged 25–29
years, which is as high as that found in countries like Colombia
(Molano et al, 2002) and Chennai, India (Franceschi et al, 2005),
where cervical cancer rates are 3–4-fold higher than in the
United Kingdom (Ferlay et al, 2010). High-quality cervical
screening is the clear explanation for the discrepancy between
high HPV prevalence and low cervical cancer incidence in England
(Peto et al, 2004).
Will HPV16/18 immunisation reduce cervical cancer incidence
any further in England and elsewhere? A few unique features of
HPV vaccines represent special challenges: (1) they are expensive
vaccines; (2) they target adolescent girls for whom no delivery
platform is readily available in any country; and (3) they are
meant to prevent a cancer for which an effective secondary
prevention strategy exists (Franceschi et al, 2009). High-quality
screening can diminish cervical cancer much more quickly
than immunisation against HPV, but it is complicated, very
expensive and very inequitably distributed within and between
world countries. The success of vaccine delivery in England gives
good reason to be optimistic. In the first year of the HPV
immunisation programme, 80% of 12–13-year-old girls (routine
cohort) received all three HPV vaccine doses (Department of
Health, 2010). Also importantly, national data show little evidence
of inequality in coverage among 12-year-old girls by deprivation
level of the areas where they live. This contrasts with a correlation
with deprivation for cervical screening uptake even in England
(Desai et al, 2010). *Correspondence: Dr S Franceschi; E-mail: franceschi@iarc.fr
British Journal of Cancer (2010) 103, 157–158
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.comHigh-vaccine uptake was also reported in similar school-based
programmes in Scotland (National Health Services Scotland,
2010), Wales (National Public Health Service for Wales, 2009),
and Australia (Brotherton et al, 2008), but is in sharp contrast
with low uptake in other high-resource countries where HPV16/18
vaccination is distributed by the private sector, regardless, to
some extent, of reimbursement policies. In the United States,
where vaccine delivery is mainly through family doctors, the
uptake of more than one vaccine dose among 13–17-year-old
girls was only 25% (Bach, 2010). In addition, at the state
level, vaccination rates in the United States were strongly and
inversely correlated with cervical cancer mortality rates and
median income (Bach, 2010). Likewise, in the European Union, no
HPV16/18 vaccination programme has been started in the poorest
Member States, where no good cervical screening in place and
where cervical cancer incidence rates are the highest (Ferlay
et al, 2010). The introduction of HPV16/18 vaccination programmes
in low- and medium-resource countries outside Europe is stalling,
and is severely threatened by the economic downturn (Butler,
2010). If HPV16/18 immunisation fails to reach women and
populations who are underserved by cervical screening, hardly any
lives will be saved.
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